Cipla Limited (CIPLA NSE) stock market data APIs
INR1485.1075
-15.6(-1.1%)
as of July 18, 2025
Try our APIs with
free plan!
Cipla Limited Financial Data Overview
Price chart is built with
Anychart
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Prev. Close
1485.1075
Open
1469.5086
High
1470.723
Low
1457.5553
52 wk Range
1320.8824-1684.0507
Market Cap
1 220 804 M
P/E Ratio
22.608
Shares Outstanding
808 M
Revenue
272 674 M
EPS
15.12
Dividends (Yield)
0.0086
Beta
0.158
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cipla Limited data using free add-ons & libraries
Get Cipla Limited Fundamental Data
Cipla Limited Fundamental data includes:
- Net Revenue: 272 674 M
- EBITDA: 70 221 M
- Earnings Per Share: 65
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: 13.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cipla Limited News
New
Tariffs should not dictate how Indian drugmakers do business, Cipla CEO says
By Rishika Sadam and Kashish Tandon MUMBAI/BENGALURU (Reuters) - Tariffs should not influence decisions at Indian drug companies, Cipla's top executive said on Friday, as the industry braces for U.S....
Cipla Ltd (BOM:500087) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ...
Quarterly Revenue: INR7,073 crore, growth of 8% YoY. EBITDA Margin: 28%, up by 184 basis points YoY and 138 basis points QoQ. Gross Margin: 68%, 166 basis points above last year's figures. Profit Afte...
Asia Book of Records Honors Cipla (Emerging Markets & Europe business unit) for Record-Breaking Doctor engagement on COPD Awareness Initiative
Cipla's (EMEU BU) 'Take Charge – I Pledge' campaign engaged 4,350 doctors across six countries, setting a new benchmark in raising COPD awareness. MUMBAI, India, Jan. 29, 2025 /PRNewswire/ -- Cipla...
India's Cipla beats Q3 profit view as strong domestic demand offset weak US sales
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
